Picton Mahoney Asset Management Purchases 213,041 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Picton Mahoney Asset Management raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 50.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 633,149 shares of the company's stock after buying an additional 213,041 shares during the period. Picton Mahoney Asset Management owned about 0.06% of Teva Pharmaceutical Industries worth $13,953,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TEVA. FMR LLC increased its stake in shares of Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Teva Pharmaceutical Industries by 7,945.2% in the third quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock worth $86,350,000 after purchasing an additional 4,732,374 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $58,243,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Teva Pharmaceutical Industries by 237.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock worth $60,863,000 after purchasing an additional 2,376,668 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TEVA. StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday, March 7th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.47 during trading on Monday, hitting $16.80. 7,372,764 shares of the company's stock traded hands, compared to its average volume of 12,843,933. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business has a fifty day simple moving average of $18.28 and a 200 day simple moving average of $18.29. The stock has a market capitalization of $19.04 billion, a price-to-earnings ratio of -11.58, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.